Can you provide the average price target for VERACYTE INC stock?
19 analysts have analysed VCYT and the average price target is 49.52 USD. This implies a price increase of 45.47% is expected in the next year compared to the current price of 34.04.
NASDAQ:VCYT • US92337F1075
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VERACYTE INC (VCYT).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-13 | Jefferies | Initiate | Buy |
| 2026-04-01 | Needham | Maintains | Buy -> Buy |
| 2026-03-30 | Guggenheim | Maintains | Buy -> Buy |
| 2026-03-06 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2026-02-26 | Needham | Maintains | Buy -> Buy |
| 2026-01-05 | Guggenheim | Maintains | Buy -> Buy |
| 2025-12-02 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2025-11-11 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2025-11-05 | Guggenheim | Maintains | Buy -> Buy |
| 2025-11-05 | UBS | Maintains | Buy -> Buy |
| 2025-11-05 | Needham | Maintains | Buy -> Buy |
| 2025-11-05 | Canaccord Genuity | Maintains | Hold -> Hold |
| 2025-10-20 | Canaccord Genuity | Initiate | Hold |
| 2025-10-17 | Freedom Capital Markets | Initiate | Buy |
| 2025-05-08 | UBS | Maintains | Buy -> Buy |
| 2025-05-08 | Needham | Maintains | Buy -> Buy |
| 2025-04-09 | Guggenheim | Maintains | Buy -> Buy |
| 2025-03-26 | Stephens & Co. | Reiterate | Overweight -> Overweight |
| 2025-03-20 | Craig-Hallum | Initiate | Buy |
| 2025-02-25 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-02-25 | UBS | Maintains | Buy -> Buy |
| 2025-02-25 | Needham | Reiterate | Buy -> Buy |
| 2025-01-29 | Needham | Maintains | Buy -> Buy |
| 2024-12-05 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2024-11-18 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 361.051M 21.77% | 445.764M 23.46% | 517.145M 16.01% | 588.28M 13.76% | 660.89M 12.34% | 729.22M 10.34% | 799.58M 9.65% | 866.59M 8.38% | 950.95M 9.73% | |
| EBITDA YoY % growth | 9.742M 182.07% | 42.969M 341.07% | 99.697M 132.02% | 147.33M 47.78% | 170.74M 15.89% | 190.48M 11.56% | 213.11M 11.88% | 236.57M 11.01% | 274.18M 15.90% | |
| EBIT YoY % growth | -17.446M 53.85% | 19.51M 211.83% | 78.282M 301.24% | 78.084M -0.25% | 105.15M 34.66% | 141.11M 34.20% | 126.43M -10.40% | 148.05M 17.10% | 195.23M 31.87% | |
| Operating Margin | -4.83% | 4.38% | 15.14% | 13.27% | 15.91% | 19.35% | 15.81% | 17.08% | 20.53% | |
| EPS YoY % growth | -1.03 -106.00% | 0.30 129.13% | 0.83 176.67% | 1.06 27.72% | 1.24 17.27% | 1.42 14.05% | 2.07 45.81% | 2.17 5.10% | 2.32 6.57% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.18 99.18% | 0.27 2,780.05% | 0.29 22.67% | 0.32 -38.07% | 0.22 23.76% | 0.27 0.86% | 0.29 -2.99% | 0.30 -5.53% | 0.41 83.91% | 0.49 81.13% | 0.50 75.00% | 0.53 77.78% |
| Revenue Q2Q % growth | 132.81M 16.02% | 146.95M 12.90% | 151.15M 14.62% | 157.61M 12.07% | 152.18M 14.58% | 164.72M 12.09% | 169.43M 12.09% | 175.38M 11.27% | 165.33M 8.64% | 183.98M 11.69% | 190.08M 12.19% | 197.96M 12.87% |
| EBITDA Q2Q % growth | 29.703M 259.34% | 36.971M 41.72% | 38.968M -0.24% | 41.764M -28.74% | 36.773M 23.80% | 42.938M 16.14% | 45.045M 15.59% | 47.513M 13.77% | 39.423M 7.21% | 49.195M 14.57% | 51.204M 13.67% | 56.222M 18.33% |
| EBIT Q2Q % growth | 15.556M 435.67% | 22.01M 44.45% | 23.753M 3.52% | 25.544M -31.32% | 23.511M 51.14% | 29.374M 33.46% | 31.367M 32.05% | 33.61M 31.58% | 36.037M 53.28% | 45.808M 55.95% | 47.705M 52.09% | 52.652M 56.66% |
All data in USD
19 analysts have analysed VCYT and the average price target is 49.52 USD. This implies a price increase of 45.47% is expected in the next year compared to the current price of 34.04.
VERACYTE INC (VCYT) will report earnings on 2026-05-05, after the market close.
The consensus EPS estimate for the next earnings of VERACYTE INC (VCYT) is 0.18 USD and the consensus revenue estimate is 132.81M USD.
The consensus rating for VERACYTE INC (VCYT) is 82.1053 / 100 . This indicates that analysts generally have a positive outlook on the stock.